Norwegian MRS (magnetic resonance spectroscopy) to improve cancer diagnosis
This article was originally published in Clinica
Executive Summary
A Norwegian research group claims to be the first to be the first to use in vivo magnetic resonance spectroscopy (MRS) to differentiate between benign and cancerous breast lesions in patients. The group, headed by Ingrid Gribbestad, senior research scientist at the Foundation for Scientific and Industrial Research at the Norwegian Institute of Technology in Trondheim, is using MRS to specifically document the presence of chemical substances in cancerous tumours.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.